In Brief: FDA considers emergency contraceptive label change, CRN points out FSMA exemptions; NAD refers Maxam claims to FTC
This article was originally published in The Tan Sheet
Executive Summary
FDA considers emergency contraceptive label change; CRN points out FSMA exemptions; NAD refers Maxam claims to FTC; P&G executives retire; nutritional product firms among top direct sellers; Boots recalls store brand products; more In Brief.
You may also be interested in...
Compliance Corner: Follow These 11 Steps To Prep For FDA Regulatory Meetings
Longtime industry expert Steve Niedelman offers manufacturers pointers so they’re not caught flatfooted during regulatory meetings with the US agency.
EMA Says Yes To Eight New Medicines, Holds Fire On Others
The European Medicines Agency today announced the new medicines it believes should be approved for use across the EU.
EU Thumbs Up Signals First-Ever Approval For Leo’s Tralokinumab
Leo’s moderate-to-severe atopic dermatitis drug is set to be approved for the first time worldwide.